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Abstract 
Background: Accumulating evidence has confirmed that miR-196a plays a critical role in tumorigenesis and tumor 
progression in a variety of cancers. It has been demonstrated that miR-196a is highly up-regulated in laryngeal cancer 
by miRNA profiling analysis. However, the functional mechanism of miR-196a in laryngeal cancer remains unclear. This 
study aims to explore the mechanism of miR-196a in laryngeal cancer.
Methods: In the present study, we conducted qPCR analysis of miR-196a expression in human laryngeal cancer and 
showed that miR-196a was overexpressed in tumor-derived samples and laryngeal cancer cell lines compared with 
matched normal controls. Further functional analysis of miR-196a demonstrated that the inhibition of miR-196a could 
inhibit laryngeal cell-cycle progression and proliferation in vitro. Luciferase reporter assay and western blot confirmed 
that miR-196a directly targeted p27kip1. Moreover, in order to investigate whether miR-196a regulated cell growth in 
laryngeal cancer cells by targeting p27kip1, rescue studies were performed in laryngeal cancer cells.
Results: Results showed that overexpression of p27kip1 rescue decreased cell proliferation caused by miR-196a 
inhibitors. A negative relation between miR-196a and p27kip1 expression in laryngeal cancer tissues were also noted 
by further analyses.
Conclusions: The present study showed that miR-196a was upregulated in laryngeal cancer and promoted cell pro-
liferation by downregulating p27kip1 in laryngeal cancer. However, further studies are needed to verify this finding.
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Background
Laryngeal squamous cell carcinoma (LSCC) is one of 
the most common cancers in incidence and mortal-
ity in the head and neck areas [1]. The dismal outcome 
of patients with laryngeal cancer has been attributed to 
late diagnosis, recurrence, and metastasis. So far, surgical 
removal or radiotherapy remains the mainstay treatment 
of laryngeal cancer, although it is curable when found 
and treated in the early phase. The prognosis for patients 
in the advanced stage is still very poor [2]. In China, the 
30-year survival rates of patients with laryngeal cancer 
has improved moderately or even decreased in part due 
to the relatively high local recurrence [3]. Hence, there 
is a pressing need to identify both novel highly sensitive 
biomarkers and new targets for therapeutic intervention 
for laryngeal cancer which may aid the diagnosis and 
improve patient outcomes.
MicroRNA (miRNA), encoding a small non-coding 
RNA of 20–22 nucleotides, is now recognized as a large 
gene family expressed in plants, animals, and viruses as 
well as in unicellular algae [4]. It acts as post-transcrip-
tional regulators by inhibiting gene expression through 
either cleavage of the target mRNA or translational 
repression [5]. The role of miRNAs in disease processes 
has received greater attention in recent years due to their 
capability of regulating a multitude of genes [6]. Natu-
rally, the aberrant expression of miRNA in the pathogen-
esis of various cancer types has been documented [7–11]. 
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Some studies have demonstrated that miRNAs are often 
significantly down-regulated in cancers and have the 
potential to act as tumor suppressors [7, 12], while oth-
ers have shown that miRNAs can also be up-regulated 
in tumors and act as oncogenes [13, 14]. For instance, 
miR-let-7a has been widely found to be down-regulated 
in several cancers including gastric [15], lung [16], breast 
[17], and prostate [18]. It functions as a tumor suppres-
sor due to its ability to inhibit oncogene target mRNAs 
such as Ras [16] and PKM2 [15]. Simultaneously, reports 
have demonstrated that miR-196a expression is signifi-
cantly higher in various types of tumors than the controls 
such as gastric [19], osteosarcoma [20], breast [21], and 
pancreatic cancers [22, 23]. Since studies have shown that 
miR-196a contributes to the development and progres-
sion of cancers, it may be useful as a candidate biomarker 
for cancer diagnosis [9].
Recently, it has been reported that miR-196a was dra-
matically up-regulated in laryngeal cancer. Also, miR-
196a inhibitor could suppress the laryngeal cancer 
growth in  vivo or in  vitro [9]. However, the regulatory 
function that miR-196a plays in laryngeal carcinoma, 
although elucidating the biologic consequences of 
miRNA dysregulation and identifying the targets of miR-
NAs, is critical to understanding miRNA pathways and 
their underlying molecular mechanisms. Recently, it 
has been reported that miR-196a promotes cancer cells 
proliferation by downregulating p27kip1 in gastric cancer 
[19]. It is of interest to investigate if similar events have 
occurred in laryngeal cancer.
In the present study, we conducted a qPCR analysis of 
miR-196a expression in human laryngeal cancer tissues 
and showed that miR-196a was overexpressed in tumor-
derived samples and laryngeal cancer cell lines compared 
with matched normal controls. Further functional analy-
sis of miR-196a demonstrated that the inhibition of miR-
196a could inhibit laryngeal cell-cycle progression and 
proliferation in vitro. Luciferase reporter assay and west-
ern blot confirmed that miR-196a may function as an 
oncogene by directly targeting p27kip1. The p27kip1-medi-
ated repression in cell proliferation was reverted by exog-
enous miR-196a expression. A negative relation between 
miR-196a and p27kip1 expression in laryngeal cancer tis-
sues was noted by consecutive further analysis. This is 
the first report that investigates miR-196a function in 
laryngeal cancer apoptosis by testing p27kip1 expression.
Methods
Patients and samples collection
The study was approved by Research Ethics Committee 
of School of Medicine, Shanghai Jiao Tong University 
(Shanghai, PR China). Informed consents were obtained 
from all patients. Laryngeal cancer tissues and normal 
tissues were obtained from patients who had undergone 
surgery at Shanghai Ren Ji Hospital. All the tissue sam-
ples were collected, immediately snap frozen in liquid 
nitrogen, and stored at −80 °C prior to RNA extraction.
Cell lines and culture condition
Human laryngeal squamous cell carcinoma HEp-2 cells 
and human laryngeal squamous cell carcinoma SNU899 
and TU212 were purchased from the Cell Bank of the 
Chinese Academy of Sciences. HEK293T cells for the 
luciferase reporter assay were purchased from the Insti-
tute of Biochemistry and Cell Biology (Shanghai). The 
human normal bronchial epithelial cell line BEAS-2B 
was obtained from the American Type Culture Col-
lection (Manassas, VA, USA). All cells were cultured in 
a DMEM medium (Gibco, USA) containing 10  % fetal 
bovine serum (FBS) (Invitrogen), 100  U/mL penicillin, 
and 100  lg/mL streptomycin at 37  °C in incubator with 
5 % CO2.
Transfection
miRNA mimic and inhibitor transfection laryngeal can-
cer cells were transfected with miR-196a mimic, miR-
196a inhibitor (Applied Biosystems), and Lipofectamine 
2000 (Invitrogen) in accordance with the manufacturers’ 
instructions. Forty-eight hour after the transfection, cells 
were harvested for further study including western blot-
ting and qPCR analyses.
RNA extraction and quantitative real‑time PCR
Total RNA was extracted from tissues samples and can-
cer cell lines with TRIzol reagent (Invitrogen). For qPCR 
RNA was reverse transcribed to cDNA from 100  ng of 
total RNA by using a Reverse Transcription Kit (Takara). 
Real-time PCR (RT-PCR) were performed with SYBR 
Green (Takara). All protocols were carried out according 
to the manufacturer’s instructions. The primer sequences 
in terms of GAPDH, miR-196a, and P27kip1 were per-
formed according to Sun et al. [19]. Real-time PCR assay 
was performed on a Step-One Plus Real-Time PCR Sys-
tem (Applied Biosystems, USA), and each RT reaction 
was performed in triplicate including no-template con-
trols. The reaction was performed in the following con-
ditions: 95  °C for 5  min, followed by 40 cycles of 95  °C 
for 15  s, and 60  °C for 50  s. The relative quantification 
of miR-196a and p27kip1 were normalized to the expres-
sion of U6 and GAPDH using the 2−ΔΔCT method, 
respectively.
Western blotting analysis
Total cell protein was abstracted from cells after trans-
fection. The concentration of the protein was measured 
using a BCA protein assay kit (Beyotime, Shanghai, 
Page 3 of 8Jin et al. Biol Res  (2016) 49:40 
China) following the manufacturer’s instruction. Samples 
were electrophoresed by using 10 % SDS-PAGE. The pro-
tein was then transferred onto a PVDF (polyvinylidene 
fluoride) membrane (Bio-Rad, USA). After blocking in 
skim milk, the membranes were incubated with specific 
antibodies. Autoradiograms were quantified by densi-
tometry (Quantity One software; Bio-Rad). β-actin was 
used as the internal reference; goat anti-p27kip1 (1:1000) 
was purchased from Sigma.
Cell proliferation assays
Cell proliferation assays were conducted using WST 
assay (Cell Counting Kit-8, Beyotime, Shanghai, China) 
in accordance with the manufacturer’s instructions.
Flow cytometry
The HEp-2 and TU212 cells transiently transfected with 
miR-negative control (miR-NC), miR-196a mimics, miR-
196a inhibitors, pEGFP-NC, and stably transfected with 
pEGFP-p27kip1 were harvested 48  h after transfection 
using trypsinization. Apoptotic cells were detected using 
an Annexin V/APC and propidium iodide (PI) apoptosis 
detection kit I (BD Pharmingen, San Diego, CA, USA) in 
accordance with the manufacturer’s recommendations. 
The cells were analyzed with a flow cytometry (FACS-
can; BD Biosciences) equipped with CellQuest software. 
Cells were distinguished into viable, dead, early apoptotic 
and apoptotic, and then the relative ratio of early apop-
totic cells were compared with the control transfection 
cells from each experiment. Cells for cell-cycle analysis 
were stained with propidium iodide for 1 h and analyzed 
by FACS can flow cytometer and CellQuest 3.3 software. 
The percentage of the cells in G0/G1, S and G2/M phase 
were counted and compared [24].
Luciferase reporter assay
MiR-196a mimics, miRNA normal control (miR-nc), and 
miR-196a inhibitors were purchased from GenePharma 
(Shanghai, China). All transfections were performed 
using Lipofectamine 2000 (Invitrogen, USA) accord-
ing to the manufacturers’ instructions. HEK 293T cells 
were placed into 48-well plates and then cotransfected 
with miR-196a inhibitor (200  ng) and either luciferase 
reporter plasmids (200 ng) containing wild-type (WT) or 
mutant type (Mut) of p27kip1 3′UTR. Forty-eight h after 
transfection, luciferase activities were measured using 
the dual-luciferase reporter assay system. The relative 
reporter activity was normalized by r-luc activity.
Statistical analysis
The data are presented as mean  ±  SD. The Students 
test and one-way ANOVA were used to conduct the 
comparison of the different protein, mRNA, luciferase 
reporter, and miRNA expression levels. Statistical analy-
ses were performed using SPSS 16.0 software. A p value 
less than 0.05 was considered statistically significant.
Results
MiR‑196a expression is upregulated in human laryngeal 
cancer tissues and cell lines
In the present study, qRT-PCR analyses were conducted 
to measure the levels of miR-196a expression in 20 laryn-
geal cancer tissues and three laryngeal cancer cell lines 
compared with normal counterparts. The expression of 
miR-196a in cancer tissues was significantly higher than 
their matched normal tissue samples (p  <  0.01), and 
was also significantly up-regulated in Hep-2 (p  <  0.01), 
TU212 (p  <  0.01), SNU899 (p  <  0.01) laryngeal cancer 
cells lines as compared with the normal cell lines (Fig. 1a, 
b). Among the three laryngeal cell lines, the miR-196a 
expression was the highest in Hep-2, followed by TU212 
cell lines and therefore used for further study.
Exogenous downregulation of miR‑196a in laryngeal 
cancer cells
In order to downregulate the expression of miR-196a, 
miR-NC, and miR-196a inhibitors were transiently trans-
fected into Hep-2 and TU212 cells, respectively. Our data 
showed that the miR-196a was significantly down-regu-
lated in both Hep-2 and TU212 cell lines following trans-
fection with miR-196a inhibitors when compared with 
the negative control and blank (Fig. 2a).
Effect of miR‑196a on cell proliferation and apoptosis 
in vitro
To evaluate the impact of miR-196a on laryngeal cancer 
cell proliferation, WST assay was conducted to detect 
cell viability. We observed significant suppression of cell 
proliferation in Hep-2 (Fig. 2b) and TU212 cell lines that 
were treated with the miR-196a inhibitor compared with 
the control (Fig. 2c), respectively.
In addition, to determine whether cell proliferation 
was influenced by apoptosis, the quantification of the 
cell numbers was analyzed by flow cytometric analysis. 
Results showed that more apoptotic cells were present 
in both Hep-2 and TU212 cells after treatment with 
the miR-196a inhibitor as compared with the control 
(Fig. 2d). To further examine whether the effect of miR-
196a on proliferation of laryngeal cells reflected cell-cycle 
arrest, cell-cycle progression was analyzed by flow cyto-
metric analysis. The results revealed that both Hep-2 
and TU212 cell lines transfected with miR-196a inhibi-
tors had an obvious cell-cycle arrest at the G0/G1phase 
(Fig. 2e).
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miR‑196a directly targets p27kip1 in laryngeal cancer cell 
lines
We cloned the wild-type 3′-UTRs of p27kip1 gene and 
inserted it into the region immediately downstream of a 
luciferase reporter gene. Subsequently, miR-196a inhibi-
tor or miR-196a mimics were transfected with different 
luciferase 3′-UTR constructs into HEK293T cells. We 
found that miR-196a significantly decreased the relative 
activity of the luciferase reporter containing the wild-
type 3′-UTR of p27kip1 mRNA (p < 0.01; Fig. 3a). To test 
whether p27kip1 mRNA is the target for miR-196a, we 
mutated the predicted binding site of miR-196a in the 
3′-UTR. However, luciferase activity did not sharply drop 
in the UTRs with mutant-binding sites when compared 
with Mut-type counterparts (Fig. 3a).
Furthermore, we determined whether miR-196a could 
regulate p27kip1 at both mRNA and protein levels. qPCR 
analyses showed that the expression of p27kip1 mRNA 
in Hep-2 cells transfected with miR-196a inhibitor or 
mimics was upregulated or downregulated compared 
with cells transfected with control, and similar events 
occurred in TU212 cells (Fig. 3b). Western blot analysis 
showed that the expression of p27kip1 protein in Hep-2 
and TU212 cells transfected with miR-196a inhibitor was 
upregulated compared with cells transfected with nega-
tive control (Fig.  4c). These data showed that miR-196a 
could regulate p27kip1 at both mRNA and protein levels.
Silencing of p27kip1 rescue decreased cell proliferation 
caused by miR‑196a inhibitor
Moreover, to investigate whether p27kip1 was involved in 
the miR-196a–induced increase in laryngeal cancer cell 
proliferation, we carried out rescue experiments. After 
transfection with miR-196a inhibitors, Hep-2 and TU212 
cells were co-transfected with si-p27kip1, respectively. 
By WST-8 assay, we observed that co-transfection of si-
p27kip1 and miR-196a inhibitors could partially rescue 
miR-196a inhibitors–decreased proliferation in Hep-2 
(Fig. 4a) and TU212 cells (Fig. 4b), respectively.
Inverse relationship between the expression of p27kip1 
and miR‑196a
To assess the relationship between p27kip1 and miR-196a 
expression in laryngeal cancer, we examined p27kip1 and 
miR-196a by qPCR in 20 pairs of laryngeal cancer tis-
sues. The results showed that p27kip1 mRNA expression 
was generally lower in laryngeal cancer tissues when 
compared with matched normal tissues. Further analy-
ses indicated that expression of miR-196a expression 
was negatively correlated with p27kip1 protein level in 
laryngeal cancer (Fig. 4c). These data suggested that the 
p27kip1 level was mostly opposite to miR-196a expression 
in laryngeal cancer. These data suggested that miR-196a 
promotes laryngeal cell proliferation through downregu-
lation of p27kip1 expression.
Fig. 1 Expression levels of miR-196a in laryngeal tissues and cell lines by real-time PCR analysis. a MiR-196a expression was examined by qRT-PCR in 
20 laryngeal tissues and in 20 adjacent noncancerous counterparts (NCs) MiR-196a was significantly higher in laryngeal tissues than their counter-
parts. b MiR-196a was also up-regulated in Hep-2, TUU212, and SNU899 laryngeal cell lines compared with normal cell line (b). *p < 0.05; **p < 0.01
(See figure on next page.)  
Fig. 2 Effect of miR-196a on cell proliferation and apoptosis. a The relative expression level of miR-196a in Hep-2 and TU212 cells, transfected with 
miR-196a negative control (miR-NC) or inhibitors, was tested by qPCR. b and c WST assay was conducted to detect the proliferation of Hep-2 cells 
and TU212 cells, respectively. d The apoptotic rates of cells were detected by flow cytometry. e The bar chart represents the percentage of cells in 
G0/G1, S, or G2/M phase, as indicated. *p < 0.05; **p < 0.01
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Fig. 3 miR-196a directly targets the p27kip1 gene. a The luciferase reporter plasmid containing wild-type or mutant p27kip1 3′-UTR was cotrans-
fected into HEK-293T cells with miR-196a mimic or mimic NC. Luciferase activity was determined by the dual luciferase assay and shown as the 
relative firefly activity normalized to Renilla activity. b The level of p27kip1 mRNA was determined by qPCR. c the expression of p27kip1 protein was 
analyzed by Western blotting. β-actin was used as control. *p < 0.05; **p < 0.01
Fig. 4 miR-196a regulated cell proliferation through targeting p27kip1. a, b siRNA of p27kip1 rescue decreased cell profileration caused by miR-
196a inhibitors in Hep-2 (a) and TU212 (b) cell lines, respectively. c An inverse relationship between the expression of p27kip1 and miR-196a was 
detected
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Discussion
It has been demonstrated that miRNAs may act as acti-
vators or inhibitors of tumor proliferation and metastasis 
[25]. MiR-196a has been identified as an oncogene and 
reported up-regulated in some tumors include laryngeal 
cancer [19–21, 23, 26]. However, no information is avail-
able on the mechanism that altered miR-196a effect on 
the growth of laryngeal cancer cell.
We found that miR-196a was dramatically up-regu-
lated in laryngeal cancer tissues and cells, which sug-
gests that high expression of miR-196a might be involved 
in laryngeal carcinogenesis. The results obtained herein 
is consistent with the report by Saito et  al. who found 
that miR-196a was highly expressed in the laryngeal 
cancer cell line JHU-011 and was also more apparent in 
laryngeal cancer tissues than normal controls [9]. It is a 
common that increased cell proliferation occurs during 
laryngeal malignant proliferation. Herein, we raised the 
possibility that miR-196a might positively regulate laryn-
geal cell proliferation and thereby may serve as an aid for 
the diagnosis of laryngeal cancer.
In order to further investigate the function of miR-
196a in laryngeal cells, we detected the viability and pro-
liferation of both Hep-2 and TU212 cells. The results of 
a WST assay showed that viability and proliferation of 
Hep-2 and TU212 cells were significantly lower in cells 
transfected with miR-196a inhibitors than those in cells 
transfected with miR-NC. Saito et al. found that the inhi-
bition of miR-196a hindered cancer cell proliferation in 
laryngeal cancer-derived cells [9], which is in keeping 
with our findings. A study reported by Sun et  al. dem-
onstrated that overexpression of miR-196a resulted in a 
marked increase in proliferation of gastric cancer [19]. 
Based on our results and those of the previously cited 
studies, it appears that miR-196a could improve the via-
bility and proliferation of laryngeal cancer cells (Hep-2 
and TU212).
In addition to inhibiting cell proliferation, we found 
that miR-196a inhibitor has the effect of promoting apop-
tosis, in terms of Hep-2 and TU212 cells. A recent report 
on lung cancer revealed that inhibition of miR-196a 
could suppress cancer cell lines A549/DDP cell prolif-
eration through the induction of cell apoptosis [27]. Cell 
proliferation in laryngeal cancer-derived cells transfected 
inhibition of miR-196a might be result directly from cell 
apoptosis.
We carried out further studies to detect the cell cycle in 
Hep-2 and TU212 cells transfected with miR-196a inhibi-
tors. The results of the cell cycle assay by flow cytometry 
indicated that miR-196a inhibitor could induce cell cycle 
progression of Hep-2 and TU212 cells arrest at the G1–S 
phase. To some extent, our observation was consistent 
with findings in gastric cancer cells, which showed that 
overexpression of miR-196a could promote gastric cell-
cycle progression and proliferation in vitro and in vivo [19].
It has been demonstrated that the cyclin-dependent 
kinase (CDK) inhibitor p27kip1 is a critical regulator 
of the G1-S transition of the cell cycle and also regu-
lates microtubule (MT) stability [28]. The Cdk inhibitor 
p27Kip1 is present at high levels in quiescent cells and is 
suppressed in tumor cells [29]. Therefore, it is known as a 
tumor suppressor gene and a fundamental negative regu-
lator of cell cycle progression [30]. Recently, studies have 
shown that p27kip1 controls the early stage of G1/S phase 
transition, which may be particularly relevant in the con-
text of tumor progression [31]. Prior to that, it has been 
reported that miR-196a is up-regulated in gastric cancer 
and promotes cell proliferation by downregulating p27kip1 
[19]. miR-196a is also observed with up-regulated expres-
sion levels in laryngeal cancer. Therefore, it is important 
to determine which gene it targets. To better understand 
the mechanism of miR-196a in laryngeal cancer, we per-
formed luciferase reporter assay, real-time PCR, and 
western blot to confirm p27kip1 is the target of miR-196a 
in laryngeal cancer cells.
We also observed that p27kip1 expression is down-
regulated in laryngeal cancer tissues and cell lines and 
negatively correlated with miR-196a expression levels. 
In addition, further experiments showed that decreased 
cell proliferation caused by miR-196a inhibitors could be 
rescued by concomitant overexpression of p27kip1, which 
contributes to the increased understanding of the role of 
miR-196a in laryngeal cancers. Therefore, it is concluded 
that miR-196a was upregulated in laryngeal cancer and 
promoted cell proliferation by downregulating p27kip1 in 
laryngeal cancer.
However, there were also some limitations in our study. 
Previous studies have demonstrated that one miRNA 
could alter the expression of a number of genes, while 
one gene could also be regulated by multiple miRNAs 
[25]. Thus, there might be other target genes regulated 
by miR-196a involved in the proliferation of laryngeal 
cancer cells. Future research should address these issues. 
Also, further studies regarding the relationship between 
miR-196a expression and tumor growth are also needed 
to develop a better understanding of miR-196a in the 
progression of laryngeal cancer.
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